Amicus Therapeutics announced that John F. Crowley, Executive Chairman of Amicus Therapeutics, will step down from the Amicus Board of Directors and assume the role of President and CEO of BIO, the Biotechnology Innovation Organization, effective March 4, 2024. Michael Raab, Lead Independent Director, will become the Chairman of the Amicus Board of Directors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on FOLD:
- Amicus Therapeutics Congratulates Executive Chairman John F. Crowley on Appointment as Next President and CEO of BIO
- Amicus files to sell 2.47M shares of common stock for holders
- Amicus reports Q3 EPS (7c), consensus (8c)
- Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate Updates
- FOLD Upcoming Earnings Report: What to Expect?
